HSPA5 and central nervous system cancer: Preclinical studies have demonstrated promising results using GRP78 inhibitors, antibodies, and other related strategies to reduce glioma cell viability and enhance chemoradiotherapy sensitivity (Table 1), highlighting the potential of GRP78-targeted approaches in advancing glioma therapy [130].